Paradigm Shift in Regulatory Science and Virtual Workshop

The U.S. Food and Drug Administration (FDA) will host a virtual workshop on September 10, 2026, to modernize the bioequivalence (BE) evaluation methods for topical and transdermal drug products. This event aims to redefine existing, complex testing methods and streamline the development process in line with technological advancements. The FDA intends to share accumulated regulatory science achievements based on the Generic Drug User Fee Amendments (GDUFA). This can be interpreted as a paradigm shift where regulatory agencies actively embrace technological innovation and adjust regulations, rather than simply issuing directives.

Overcoming Technical Challenges and Modernizing Evaluation Standards for Topical and Transdermal Products

Topical and transdermal products, such as lidocaine patches and fentanyl patches, pose challenges in measuring their rate and extent of absorption into the body. Previously, large-scale, costly in vivo clinical trials involving many patients were required. However, this workshop will focus on alternative approaches using physicochemical and structural (Q3) analysis and modeling techniques. The FDA has already finalized the structural (Q3) analysis guidelines in March 2026 and will release the final adhesion evaluation proposal in August, laying the groundwork for regulatory easing. With the establishment of new standards, in vitro testing alone will be sufficient to demonstrate bioequivalence with the original drug.

Reduced Costs and Timeframes Due to Easing of In Vivo Clinical Trials

If the bioequivalence demonstration process is reorganized to focus on in vitro and simulation methods, the research and development costs for generic drug manufacturers will be significantly reduced. In the past, clinical trials involving direct patient recruitment typically required millions of dollars and several years, posing a high barrier to entry for small and medium-sized pharmaceutical companies. With the resolution of regulatory uncertainties and increased prospects for expedited review (ANDA) approval, products can be launched on the market in a timely manner. This will have a positive impact by providing patients with affordable treatment options to replace expensive original drugs.

Changes in Market Entry Barriers for Global Generic Companies and Increased Competition

The topical and transdermal drug delivery market is expected to exceed $200 billion in 2025, making it a key battleground for major generic companies. Global generic leaders such as Teva (TEVA) and Viatris (VTRS), as well as complex generic specialists like Amril Pharmaceuticals (AMRX), are expected to be the biggest beneficiaries of this easing. However, easing development barriers may lead to the entry of more latecomers, intensifying price competition, which can be a double-edged sword for existing leading companies. Therefore, leading companies are expected to accelerate the development of high-value-added fusion products, such as microneedles.

GDUFA-Based Regulatory Harmonization and Prospects for Future Standard Guidelines

The feedback exchanged in this workshop will serve as the basis for the final product-specific guidelines to be established in the future. The FDA is accelerating its efforts by sequentially releasing the final pharmacokinetics (PK) guidelines in May 2026 and revising the topical corticosteroid guidelines in July. This is expected to have a strong impact on global pharmaceutical regulatory harmonization (ICH) and become an opportunity to redefine global generic drug approval standards. Investors need to carefully track the extent of the easing of individual guidelines that will be finalized after the workshop and refine the commercialization speed of their pipeline assets accordingly.